Biotech

All Articles

Regeneron's Opdualag competitor reveals 57% action rate

.Regeneron is actually back along with long-term follow-up for its LAG-3 prevention and also PD-1 pr...

AstraZeneca articles records on internal rivals to AbbVie, Pfizer ADCs

.AstraZeneca has actually shared a very early consider the efficiency of its internal antibody-drug ...

iTeos- GSK's TIGIT star shows relevant renovation

.After declaring a phase 3 launch based on positive midstage end results, iTeos as well as GSK are e...

More joint FDA can speed up uncommon illness R&ampD: file

.The FDA needs to be actually even more available and collective to unleash a surge in approvals of ...

Zenas, MBX, Bicara head to Nasdaq in hot day for biotech IPOs

.It is actually an uncommonly hectic Friday for biotech IPOs, along with Zenas BioPharma, MBX and al...

Atea's COVID antiviral stops working to halt hospital stays in period 3

.Atea Pharmaceuticals' antiviral has failed yet another COVID-19 test, but the biotech still keeps o...

Neurocrine's proposal to spare schizophrenia prospect falls short

.Neurocrine Biosciences' mental illness course pivot has actually stopped working. The biotech was a...

Sanofi pays out $110M upfront for late-stage radioligand treatment

.Sanofi has created a late entrance to the radioligand gathering, spending one hundred million euros...

F 2G rears $100M for 2nd effort to obtain brand-new antifungal to market

.After F2G's very first attempt to obtain a brand-new course of antifungal to market was actually de...

Moderna targets $1.1 B in R&ampD spending slices, falls 5 programs among profitability stress

.Moderna has vowed to cut R&ampD costs by $1.1 billion by 2027. The selection to retract the spendin...